AstraZeneca PLC (AZN)vsMiniMed Group, Inc. Common Stock (MMED)
AZN
AstraZeneca PLC
$184.74
-1.40%
HEALTHCARE · Cap: $287.11B
MMED
MiniMed Group, Inc. Common Stock
$11.79
+0.94%
HEALTHCARE · Cap: $3.40B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 1865% more annual revenue ($58.74B vs $2.99B). AZN leads profitability with a 17.4% profit margin vs -10.7%. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
MMED
Hold38
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+4.0%
Fair Value
$214.34
Current Price
$184.74
$29.60 discount
Intrinsic value data unavailable for MMED.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Earnings expanding 53.9% YoY
Every $100 of equity generates 23 in profit
Strong operational efficiency at 21.6%
Generating 1.8B in free cash flow
15.0% revenue growth
Areas to Watch
Expensive relative to growth rate
Moderate valuation
4.1% revenue growth
Distress zone — elevated risk
0.0% earnings growth
ROE of 0.0% — below average capital efficiency
Currently unprofitable
Operating margin of -11.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, EPS Growth, Return on Equity. Profitability is solid with margins at 17.4% and operating margin at 21.6%.
Bull Case : MMED
The strongest argument for MMED centers on Revenue Growth. Revenue growth of 15.0% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are PEG Ratio, P/E Ratio, Revenue Growth.
Bear Case : MMED
The primary concerns for MMED are EPS Growth, Return on Equity, Profit Margin.
Key Dynamics to Monitor
AZN profiles as a value stock while MMED is a turnaround play — different risk/reward profiles.
MMED is growing revenue faster at 15.0% — sustainability is the question.
AZN generates stronger free cash flow (1.8B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
AZN scores higher overall (64/100 vs 38/100), backed by strong 17.4% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
MiniMed Group, Inc. Common Stock
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
Minimed Group, Inc. is a medical technology company that develops, manufactures, and markets medical equipment for the management of diabetes. The company is headquartered in Northridge, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?